Spring Bank Pharmaceuticals in Clinical Collaboration With Roche
February 25 2020 - 8:57AM
Dow Jones News
By Chris Wack
Spring Bank Pharmaceuticals Inc. said Tuesday it has entered
into a new clinical collaboration with Roche to explore the
co-administration of SB 11285, Spring Bank's
intravenously-administered stimulator of interferon gene agonist
with Roche's PD-L1 checkpoint inhibitor atezolizumab in patients
with advanced solid tumors.
Spring Bank dosed the first patient in the monotherapy dose
escalation component of the intravenously-administered SB 11285
Phase 1a trial in the fourth quarter. This monotherapy dose
escalation component will be followed by a combination dose
escalation of IV SB 11285 with checkpoint inhibitor nivolumab and
with atezolizumab as an additional arm added to the combination
dose escalation segment of the Phase 1a trial.
By the end of 2020, Spring Bank said it plans to generate
sufficient data from its Phase 1a/1b IV agonist program to enable
advancement into a Phase 2 clinical trial.
The Phase 1b trial will explore IV SB 11285 antitumor activity
in combination with a checkpoint inhibitor in selected tumor types.
The trial is being conducted at multiple sites in the U.S.
Spring Bank shares were up 25% to $1.50 premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 25, 2020 08:42 ET (13:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024